facebook
Subscribe50$/product give away!


Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

DEXMEDETOMIDINE HCL injection


  1. Patient Information
  2. Manufactured By:
  3. Distributed By:

Patient Information 

Dexmedetomidine hydrochloride is indicated for short-term intravenous sedation. Dosage must be individualized and titrated to the desired clinical effect. Blood pressure, heart rate and oxygen levels will be monitored both continuously during the infusion of dexmedetomidine hydrochloride and as clinically appropriate after discontinuation.

  • When dexmedetomidine hydrochloride is infused for more than 6 hours, patients should be informed to report nervousness, agitation, and headaches that may occur for up to 48 hours.

  • Additionally, patients should be informed to report symptoms that may occur within 48 hours after the administration of dexmedetomidine hydrochloride such as: weakness, confusion, excessive sweating, weight loss, abdominal pain, salt cravings, diarrhea, constipation, dizziness or light-headedness.

Manufactured By: 

HIKMA FARMAC UTICA (PORTUGAL), S.A.

Estrada do Rio da M , 8, 8A e 8B Ferven a 2705-906 Terrugem SNT, PORTUGAL

Distributed By: 

West-Ward Pharmaceuticals

Eatontown, NJ 07724 USA

Revised May 2017

PIN410-WES/4



Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: pharmacyhq.mail@gmail.com